Bristol-Myers $74 bln deal needs surgery

Wellington Management has told the board of Bristol-Myers Squibb that it does not support the company’s $74 billion acquisition of Celgene, it said on Feb. 27. The fund manager owns about 8 percent of the drugmakers’ shares.

Wellington said the deal was too risky and offered Bristol-Myers shares at a price well below implied asset value, that management was underestimating the difficulty of successful execution, and that there were “alternative paths to create value” which could be more attractive to Bristol-Myers. Dodge & Cox, the company’s fifth-largest shareholder, is also unhappy with the deal, according to sources cited by Reuters.

Starboard Value, an activist fund, also said it was against the deal on Feb. 28 and that, should the acquisition be voted down, it would nominate a slate of directors to Bristol-Myers’ board.

ReutersBiz rob_cyran PLEASE STOP, THE LENGTH OF YOUR NAME IS GOING TO REACH CRITICAL MASS.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisitionSynergies almost never end up creating the shareholder value expected. See KHC over last 2 years.
Source: CNBC - 🏆 12. / 72 Read more »

Activist investor Starboard Value says it will oppose Bristol-Myers' deal for CelgeneThe activist investor said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
Source: CNBC - 🏆 12. / 72 Read more »

Starboard Details Opposition to Bristol-Myers Deal for CelgeneActivist investor Starboard Value detailed its opposition to Bristol-Myers Squibb’s proposed acquisition of Celgene, describing the proposed takeover as poorly conceived and ill advised. CNBC Faber reported that WELLINGTON MGT. was the force behind the deal-break, even tho their voting rights aren't as large as their holdings. Also that STARBD held comparatively little stock. Was he wrong ?
Source: WSJ - 🏆 98. / 63 Read more »

Activist investor Starboard Value says it will oppose Bristol-Myers' deal for CelgeneThe activist investor said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
Source: CNBC - 🏆 12. / 72 Read more »